Ticlopidine, a cholestatic liver injury-inducible drug, causes dysfunction of bile formation via diminished biliary secretion of phospholipids: Involvement of biliary-excreted glutathione-conjugated ticlopidine metabolites

Molecular Pharmacology

Volumn 83, Issue 2, 2013, Pages 552-562

  Yoshikado, Takashi ^a,b   Takada, Tappei ^a   Yamamoto, Hideaki ^a   Tan, Jeng Kae ^a   Ito, Kousei ^a   Santa, Tomofumi ^b   Suzuki, Hiroshi ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CYTOCHROME P450; GLUTATHIONE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; PROADIFEN; TAUROCHOLIC ACID; TICLOPIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE; BILE SECRETION; CONTROLLED STUDY; CYTOTOXICITY; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIVER INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; BILIARY TRACT; BIOLOGICAL TRANSPORT; CHOLESTASIS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG-INDUCED LIVER INJURY; GLUTATHIONE; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; P-GLYCOPROTEINS; PHOSPHOLIPIDS; RATS; RATS, SPRAGUE-DAWLEY; TAUROCHOLIC ACID; TICLOPIDINE;

EID: 84872705328     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.081752     Document Type: Article

References (42)

1. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, and Kaplowitz N et al. (2011) Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 89:806-815.
2. Alberti L and Alberti-Flor JJ (2002) Ticlopidine-induced cholestatic hepatitis successfully treated with corticosteroids. Am J Gastroenterol 97:1072.
3. Ariyoshi N, Iga Y, Hirata K, Sato Y, Miura G, Ishii I, Nagamori S, and Kitada M (2010) Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese. Drug Metab Pharmacokinet 25:298-306.
4. Cava F, Gonzalez J, Gonzalez-Buitrago JM, Muriel C, and Jimenez R (1991) Inhibition of biliary cholesterol and phospholipid secretion by cefmetazole. The role of vesicular transport and of canalicular events. Biochem J 275:591-595.
5. Crocenzi FA, Mottino AD, Cao J, Veggi LM, Pozzi EJ, Vore M, Coleman R, and Roma MG (2003) Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats. Am J Physiol Gastrointest Liver Physiol 285:G449-G459.
6. Dawson S, Stahl S, Paul N, Barber J, and Kenna JG (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 40:130-138.
7. Deng X, Luyendyk JP, Ganey PE, and Roth RA (2009) Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev 61: 262-282.
8. Ebihara A, Aoki N, Yoshida N, Sano M, Matsubayashi K, Suzuki T (1978) Clinical pharmacology of a new anti-thrombotic agent, ticlopidine. Rinsho Yakuri 9:395-402.
9. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, and Meier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69: 223-231.
10. Fouassier L, Kinnman N, Lefèvre G, Lasnier E, Rey C, Poupon R, Elferink RP, and Housset C (2002) Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J Hepatol 37:184-191.
11. Funk C, Ponelle C, Scheuermann G, and Pantze M (2001) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 59:627-635.
12. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, and Meier PJ (1998) The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273:10046-10050.
13. Greany JJ, Jr, Hess DA, and Mahoney CD (1993) Ticlopidine-induced cholestatic jaundice. Clin Pharm 12:398-399.
14. Groen A, Romero MR, Kunne C, Hoosdally SJ, Dixon PH, Wooding C, Williamson C, Seppen J, Van den Oever K, and Mok KS et al. (2011) Complementary functions of the flippase ATP8B1 and the floppase ABCB4 in maintaining canalicular membrane integrity. Gastroenterology 141:1927-1937, e1-e4.
15. Grimm IS and Litynski JJ (1994) Severe cholestasis associated with ticlopidine. Am J Gastroenterol 89:279-280.
16. Hirata K, Takagi H, Yamamoto M, Matsumoto T, Nishiya T, Mori K, Shimizu S, Masumoto H, and Okutani Y (2008) Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 8:29-33.
17. Horikawa M, Kato Y, Tyson CA, and Sugiyama Y (2003) Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet 18:16-22.
18. Huang L, Smit JW, Meijer DK, and Vore M (2000) Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats. Hepatology 32:66-72.
19. Ikebuchi Y, Takada T, Ito K, Yoshikado T, Anzai N, Kanai Y, and Suzuki H (2009) Receptor for activated C-kinase 1 regulates the cellular localization and function of ABCB4. Hepatol Res 39:1091-1107.
20. Iqbal M, Goenka P, Young MF, Thomas E, and Borthwick TR (1998) Ticlopidine-induced cholestatic hepatitis: report of three cases and review of the literature. Dig Dis Sci 43:2223-2226.
21. Lee J and Boyer JL (2000) Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders. Semin Liver Dis 20:373-384.
22. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
23. Mambelli E, Mancini E, Casanova S, Di Felice A, and Santoro A (2007) Severe ticlopidine-induced cholestatic syndrome. Blood Purif 25:441-445.
24. Morita SY, Kobayashi A, Takanezawa Y, Kioka N, Handa T, Arai H, Matsuo M, and Ueda K (2007) Bile salt-dependent efflux of cellular phospholipids mediated by ATP binding cassette protein B4. Hepatology 46:188-199.
25. Moschetta A, vanBerge-Henegouwen GP, Portincasa P, Palasciano G, Groen AK, and van Erpecum KJ (2000) Sphingomyelin exhibits greatly enhanced protection compared with egg yolk phosphatidylcholine against detergent bile salts. J Lipid Res 41:916-924.
26. Mottino AD, Cao J, Veggi LM, Crocenzi F, Roma MG, and Vore M (2002) Altered localization and activity of canalicular Mrp2 in estradiol-17beta-D- glucuronide-induced cholestasis. Hepatology 35:1409-1419.
27. Oude Elferink RP and Paulusma CC (2007) Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch 453:601-610.
28. Oude Elferink RP, Paulusma CC, and Groen AK (2006) Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology 130:908-925.
29. Pauli-Magnus C and Meier PJ (2006) Hepatobiliary transporters and drug-induced cholestasis. Hepatology 44:778-787.
30. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, Scheper RJ, Borst P, and Oude Elferink RP (1996) Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271:1126-1128.
31. Rahman I, Kode A, and Biswas SK (2006) Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 1:3159-3165.
32. Shimizu S, Atsumi R, Nakazawa T, Fujimaki Y, Sudo K, and Okazaki O (2009) Metabolism of ticlopidine in rats: identification of the main biliary metabolite as a glutathione conjugate of ticlopidine S-oxide. Drug Metab Dispos 37:1904-1915.
33. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, and van Roon MA et al. (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75:451-462.
34. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, and Meier PJ (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422-430.
35. Stieger B, Meier Y, and Meier PJ (2007) The bile salt export pump. Pflugers Arch 453:611-620.
36. Takikawa H, Sano N, Wako Y, and Yamanaka M (1993) Effects of organic anions and bile acids on biliary lipid excretion in hyperbilirubinemic mutant Sprague-Dawley rats. J Hepatol 17:247-252.
37. Takikawa H and Onji M (2005) A proposal of the diagnostic scale of drug-induced liver injury. Hepatol Res 32:250-251.
38. van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, and van Meer G (1996) MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87: 507-517.
39. Verkade HJ, Wolbers MJ, Havinga R, Uges DR, Vonk RJ, and Kuipers F (1990) The uncoupling of biliary lipid from bile acid secretion by organic anions in the rat. Gastroenterology 99:1485-1492.
40. Wagner H, Hoerhammer L, and Wolff P (1961) Thin layer chromatography of phosphatides and glycolipids [German]. Biochem Z 334:175-184.
41. Yang KH, Choi YH, Lee U, Lee JH, and Lee MG (2009) Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism. J Pharm Pharmacol 61:47-54.
42. Yoshikado T, Takada T, Yamamoto T, Yamaji H, Ito K, Santa T, Yokota H, Yatomi Y, Yoshida H, and Goto J et al. (2011) Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol Pharmacol 79:241-250.